Clinical Trial of Vigabatrin as Adjunctive Therapy in Children with Refractory Epilepsy

Mahmoud-Reza Ashrafi; Mohammad-Mahdi  Taghdiri; Mohammad-Kazem  Bakhshandeh-Bali; Seyedeh-Mohadeseh Taheri-Otaghsara; Mohammad-Mahdi Nasehi; Mohammad Ghofrani

IJ Pediatrics

The Scientific Journal of Growth & Development Research Center

Outlines

Abstract
References
Copyright

Clinical Trial of Vigabatrin as Adjunctive Therapy in Children with Refractory Epilepsy

Author(s):

Mahmoud-Reza Ashrafi^1,*,

Mohammad-Mahdi Taghdiri²,

Mohammad-Kazem Bakhshandeh-Bali³,

Seyedeh-Mohadeseh Taheri-Otaghsara⁴,

Mohammad-Mahdi Nasehi⁵,

Mohammad Ghofrani⁶

IJ Pediatrics:Vol. 23, issue 6; 653-658

Published online:Nov 22, 2013

Article type:Research Article

Received:Apr 13, 2013

Accepted:Oct 22, 2013

How to Cite:Mahmoud-Reza AshrafiMohammad-Mahdi TaghdiriMohammad-Kazem Bakhshandeh-BaliSeyedeh-Mohadeseh Taheri-OtaghsaraMohammad-Mahdi NasehiMohammad Ghofraniet al.Clinical Trial of Vigabatrin as Adjunctive Therapy in Children with Refractory Epilepsy.Iran J Pediatr.23(6):653-658.

Abstract

Objective: Approximately one-third of all children with epilepsy do not achieve complete seizure improvement. This study evaluated the efficacy of Vigabatrin in children with intractable epilepsy. Methods: From November 2011 to October 2012, 73 children with refractory epilepsy (failure of seizure control with the use of two or more anticonvulsant drugs) who were referred to the Children’s Medical Center and Mofid Children’s Hospital were included in the study. The patients were treated with Vigabatrin in addition to their previous medication, and followed-up after three to four weeks to determine the daily frequency, severity, and duration of seizures in addition to any reported side effects. Findings: Of the 67 children, 41 (61.2%) were males and 26 (38.8%) females, their age ranging from three months to 13 years with an average of 3.1 [standard deviation (SD), 2.6] years. The mean daily frequency of seizures at baseline was 6.61 (SD, 5.9) seizures per day. Vigabatrin reduced the seizure frequency ≤2.9 (SD, 5.2) (56% decline) and 3.0 (SD, 5.3) (54.5% decline) per day after three and six months of treatment, respectively. A significant difference was observed between seizure frequencies at three (P

Keywords

Fulltext

Click here to download PDF.

References

1.
References are available on the PDF.

comments